Abstract
An unmet clinical need exists in the management of treatment-refractory allergic bronchopulmonary aspergillosis (ABPA). Omalizumab has shown promising effects in case series and cohort studies; however, evidence to support its routine clinical use is lacking. The aim of this systematic review and meta-analysis was to evaluate the clinical effectiveness and safety of omalizumab in patients with ABPA. A systematic search across standard databases was conducted using specific keywords until May 13, 2021. A meta-analysis was performed to compare the effectiveness (exacerbations, oral corticosteroid [OCS] use, lung function, patient-reported asthma control) and safety of pre- and post- omalizumab treatment. Subgroup analyses were performed for treatment duration and underlying disease. In total, 49 studies (n=267) were included in the qualitative synthesis and 14 case series (n=186) in the quantitative meta-analysis. Omalizumab treatment significantly reduced the annualized exacerbation rate versus pre-treatment (mean difference
| Original language | English |
|---|---|
| Pages (from-to) | 896-905 |
| Number of pages | 10 |
| Journal | The Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 11 |
| Issue number | 3 |
| Early online date | 26 Dec 2022 |
| DOIs | |
| Publication status | Early online date - 26 Dec 2022 |
Keywords
- omalizumab
- allergic bronchopulmonary aspergillosis
- lung function
- cystic fibrosis
- ACT score
- asthma
- exacerbations
- meta-analysis
- oral corticosteroids